IL155436A0 - Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists - Google Patents
Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonistsInfo
- Publication number
- IL155436A0 IL155436A0 IL15543601A IL15543601A IL155436A0 IL 155436 A0 IL155436 A0 IL 155436A0 IL 15543601 A IL15543601 A IL 15543601A IL 15543601 A IL15543601 A IL 15543601A IL 155436 A0 IL155436 A0 IL 155436A0
- Authority
- IL
- Israel
- Prior art keywords
- phenylaminoimidazoline
- antagonists
- substituted
- phenyl ketone
- ketone derivatives
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- XSDRNCZRJVKAFM-UHFFFAOYSA-N diphenylmethanone;n-phenyl-4,5-dihydro-1h-imidazol-2-amine Chemical class N1CCN=C1NC1=CC=CC=C1.C=1C=CC=CC=1C(=O)C1=CC=CC=C1 XSDRNCZRJVKAFM-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24888800P | 2000-11-14 | 2000-11-14 | |
PCT/EP2001/012776 WO2002040453A1 (en) | 2000-11-14 | 2001-11-05 | Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL155436A0 true IL155436A0 (en) | 2003-11-23 |
Family
ID=22941114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15543601A IL155436A0 (en) | 2000-11-14 | 2001-11-05 | Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1339694B1 (es) |
JP (1) | JP4108474B2 (es) |
KR (1) | KR100562605B1 (es) |
CN (1) | CN1267423C (es) |
AR (1) | AR035502A1 (es) |
AT (1) | ATE305002T1 (es) |
AU (1) | AU2180802A (es) |
BG (1) | BG107814A (es) |
BR (1) | BR0115291A (es) |
CA (1) | CA2427900A1 (es) |
CZ (1) | CZ20031596A3 (es) |
DE (1) | DE60113563T2 (es) |
EC (1) | ECSP034602A (es) |
ES (1) | ES2248413T3 (es) |
HU (1) | HUP0303156A3 (es) |
IL (1) | IL155436A0 (es) |
MA (1) | MA26958A1 (es) |
MX (1) | MXPA03004073A (es) |
NO (1) | NO20032142L (es) |
NZ (1) | NZ525330A (es) |
PA (1) | PA8532201A1 (es) |
PE (1) | PE20020602A1 (es) |
PL (1) | PL362549A1 (es) |
RU (1) | RU2284995C2 (es) |
SK (1) | SK7222003A3 (es) |
UY (1) | UY27023A1 (es) |
WO (1) | WO2002040453A1 (es) |
YU (1) | YU37203A (es) |
ZA (1) | ZA200303413B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1596858A1 (en) * | 2003-02-14 | 2005-11-23 | Medical Research Council | Ip receptor antagonists for the treatment of pathological uterine conditions |
BRPI0409957A (pt) * | 2003-05-01 | 2006-04-25 | Hoffmann La Roche | imidazolin-2-ilaminofenil amidas |
US20070060593A1 (en) * | 2003-06-25 | 2007-03-15 | Kerns Jeffrey K | 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3 |
CN1849308A (zh) | 2003-07-09 | 2006-10-18 | 弗·哈夫曼-拉罗切有限公司 | 硫代苯基氨基咪唑啉 |
EP1981498A2 (en) * | 2006-01-27 | 2008-10-22 | F. Hoffmann-la Roche AG | Use of 2-imidazoles for the treatment of cns disorders |
ES2381589T3 (es) | 2006-10-19 | 2012-05-29 | F. Hoffmann-La Roche Ag | Aminometil-4-imidazoles |
WO2008052907A1 (en) | 2006-11-02 | 2008-05-08 | F. Hoffmann-La Roche Ag | Substituted 2-imidazoles as modulators of the trace amine associated receptors |
RU2456281C2 (ru) | 2006-11-16 | 2012-07-20 | Ф. Хоффманн-Ля Рош Аг | Замещенные 4-имидазолы, способ их получения и их применение |
AU2007332641A1 (en) | 2006-12-13 | 2008-06-19 | F. Hoffmann-La Roche Ag | Novel 2 -imidazoles as ligands for trace amine associated receptors (TAAR) |
US20080146523A1 (en) | 2006-12-18 | 2008-06-19 | Guido Galley | Imidazole derivatives |
RU2473545C2 (ru) | 2007-02-02 | 2013-01-27 | Ф.Хоффманн-Ля Рош Аг | Новые 2-аминооксазолины в качестве лигандов taar1 для заболеваний цнс |
RU2460725C2 (ru) | 2007-02-15 | 2012-09-10 | Ф. Хоффманн-Ля Рош Аг | Новые 2-аминооксазолины в качестве лигандов taar1 |
MX2009013742A (es) | 2007-07-02 | 2010-01-26 | Hoffmann La Roche | 2-imidazolinas. |
AU2008270444A1 (en) | 2007-07-03 | 2009-01-08 | F. Hoffmann-La Roche Ag | 4-imidazolines and their use as antidepressants |
RU2010104632A (ru) | 2007-07-27 | 2011-09-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | 2-азетидинметанамины и 2-пирролидинметанамины в качестве лигандов taar |
JP5341084B2 (ja) | 2007-08-03 | 2013-11-13 | エフ.ホフマン−ラ ロシュ アーゲー | Taar1リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体 |
US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
EP2513064B1 (en) | 2009-12-17 | 2018-07-04 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Compounds, compositions and methods for controlling biofilms |
US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
US9295665B2 (en) | 2013-03-12 | 2016-03-29 | Allergan, Inc. | Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors |
US9321745B2 (en) | 2013-03-12 | 2016-04-26 | Allergan, Inc. | Inhibition of neovascularization by inhibition of prostanoid IP receptors |
US9827225B2 (en) * | 2016-01-25 | 2017-11-28 | Jenivision Inc. | Use of prostacyclin antagonists for treating ocular surface nociception |
RU2731095C2 (ru) | 2016-03-17 | 2020-08-28 | Ф. Хоффманн-Ля Рош Аг | Производное 5-этил-4-метил-пиразол-3-карбоксамида, обладающее активностью агониста taar |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4889868A (en) * | 1984-12-20 | 1989-12-26 | Rorer Pharmaceutical Corporation | Bis-imidazolinoamino derivatives as antiallergy compounds |
GB9506188D0 (en) * | 1995-03-27 | 1995-05-17 | Fujisawa Pharmaceutical Co | Amidine derivatives |
NZ331480A (en) * | 1997-09-04 | 2000-02-28 | F | 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions |
-
2001
- 2001-11-05 HU HU0303156A patent/HUP0303156A3/hu unknown
- 2001-11-05 RU RU2003115426/04A patent/RU2284995C2/ru not_active IP Right Cessation
- 2001-11-05 CN CNB018187471A patent/CN1267423C/zh not_active Expired - Fee Related
- 2001-11-05 BR BR0115291-2A patent/BR0115291A/pt not_active IP Right Cessation
- 2001-11-05 ES ES01996531T patent/ES2248413T3/es not_active Expired - Lifetime
- 2001-11-05 YU YU37203A patent/YU37203A/sh unknown
- 2001-11-05 AU AU2180802A patent/AU2180802A/xx not_active Withdrawn
- 2001-11-05 AT AT01996531T patent/ATE305002T1/de not_active IP Right Cessation
- 2001-11-05 SK SK722-2003A patent/SK7222003A3/sk unknown
- 2001-11-05 IL IL15543601A patent/IL155436A0/xx unknown
- 2001-11-05 NZ NZ525330A patent/NZ525330A/en unknown
- 2001-11-05 EP EP01996531A patent/EP1339694B1/en not_active Expired - Lifetime
- 2001-11-05 PL PL01362549A patent/PL362549A1/xx unknown
- 2001-11-05 CZ CZ20031596A patent/CZ20031596A3/cs unknown
- 2001-11-05 DE DE60113563T patent/DE60113563T2/de not_active Expired - Fee Related
- 2001-11-05 MX MXPA03004073A patent/MXPA03004073A/es active IP Right Grant
- 2001-11-05 JP JP2002542781A patent/JP4108474B2/ja not_active Expired - Fee Related
- 2001-11-05 KR KR1020037006504A patent/KR100562605B1/ko not_active IP Right Cessation
- 2001-11-05 CA CA002427900A patent/CA2427900A1/en not_active Abandoned
- 2001-11-05 WO PCT/EP2001/012776 patent/WO2002040453A1/en active IP Right Grant
- 2001-11-09 PE PE2001001118A patent/PE20020602A1/es not_active Application Discontinuation
- 2001-11-13 UY UY27023A patent/UY27023A1/es not_active Application Discontinuation
- 2001-11-13 AR ARP010105280A patent/AR035502A1/es not_active Application Discontinuation
- 2001-11-13 PA PA20018532201A patent/PA8532201A1/es unknown
-
2003
- 2003-05-02 ZA ZA200303413A patent/ZA200303413B/en unknown
- 2003-05-12 MA MA27154A patent/MA26958A1/fr unknown
- 2003-05-13 EC EC2003004602A patent/ECSP034602A/es unknown
- 2003-05-13 NO NO20032142A patent/NO20032142L/no not_active Application Discontinuation
- 2003-05-14 BG BG107814A patent/BG107814A/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL155436A0 (en) | Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists | |
IL162388A0 (en) | Substituted phenyl derivatives | |
IL152209A0 (en) | Benzoamide piperidine compounds as substance p antagonists | |
AU5216801A (en) | Carboxylic acid derivatives as ip antagonists | |
IL153224A0 (en) | 1,4-dihydropyridines as bradykinin antagonists | |
HUP0303449A3 (en) | Substituted benzofuran-2-carboxamides derivatives | |
HK1061018A1 (en) | Substituted c-cyclohexylmethylamine derivatives | |
ID29914A (id) | Senyawa benzensulfonamida heterosiklik sebagai antagonis bradikinin | |
IL148623A0 (en) | Thienoisoxazolyl-and thienylpyrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists | |
GB0120818D0 (en) | Heterocyclic compounds | |
HK1052925B (zh) | 取代的1-氨基丁-3-醇衍生物 | |
PL364873A1 (en) | Substituted aminomethyl-phenyl-cyclohexane derivatives | |
AU5884101A (en) | Heterocyclic compounds | |
ID27845A (id) | Turunan tetrahidrokuilina sebagai antagonis glisilina | |
AU2001258841A1 (en) | Heterocyclic compounds | |
DE60210058D1 (de) | Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten | |
PL369829A1 (en) | Substituted 1h-quinolin-2-one compounds | |
IL155104A0 (en) | 5-amino-1-pentene-3-ol substituted derivatives | |
GB0022828D0 (en) | New herbicidal composition | |
SI1406888T1 (sl) | Substituirane gama-laktonske spojine kot NMDA antagonisti | |
SI1322590T1 (sl) | Substituirani 5-amino-1-penten-3-olni derivati | |
AU2002341261A1 (en) | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists | |
GB2394621B (en) | Integrated ip network | |
GB0009125D0 (en) | Antagonists | |
GB0006860D0 (en) | Antagonists |